Teicoplanin Matches Standard Care With Less Nephrotoxicity in Bacteremia
This propensity-matched cohort supports teicoplanin as a renal-sparing alternative for Gram-positive bacteremia, contingent on adequate loading dosing and appropriate infection-site selection.
Teicoplanin matches standard antibiotics but reduces nephrotoxicity risk.
Understanding the comparative effectiveness of teicoplanin vs standard antibiotics can guide treatment for Gram-positive bacteremia while minimizing nephrotoxicity. Teicoplanin showed similar clinical cure rates to standard-of-care antibiotics but with significantly lower nephrotoxicity (6.8% vs 18.2%). Teicoplanin may be a viable alternative, especially for patients at risk for renal issues. However, efficacy varied with infection source, being lower in pneumonia and endocarditis. Teicoplanin is as effective as standard antibiotics with less nephrotoxicity for treating Gram-positive bacteremia.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Alawad E, Assiri T, Alharthi M, Akrash AB, Alsherbeeni N, Bahloul A, Alraddadi M, Alharbi D, Kardam A
Citation:Alawad E, Assiri T, Alharthi M, et al. Comparative Effectiveness of Teicoplanin Versus Standard of Care Antibiotics for the Treatment of Gram-Positive Bacteremia: A Seven-Year Retrospective Analysis. Open forum infectious diseases. 2026;13(7):ofag462. doi:10.1093/ofid/ofag462
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.